| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5ad8562c578b061df7a2c3aee9d0e24 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 |
| filingDate |
2002-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f917cccb065087f9f3457813e190722
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_275b58688e6777c09ed6cb98845b43d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cbaad14c0a43308731c345cf456e1e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42369e42db1f0de29744be622ae3c43d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f9d1de535a5f1f4386a0ba5ae1531ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7d554b0b0326416f95c1075ce4a8829 |
| publicationDate |
2004-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20040009018-A |
| titleOfInvention |
P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient |
| abstract |
The present invention relates to a novel use of octylonium bromide as a p-glycoprotein inhibitor for increasing cellular uptake of a drug. More specifically, the present invention relates to octylonium as a p-glycoprotein inhibitor that enhances intracellular uptake and bioavailability of the drug when administered orally before or concurrently with a drug such as an anticancer agent by inhibiting the p-glycoprotein. Provide bromide. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200120264-A |
| priorityDate |
2002-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |